Kura licenses leukemia drug to Japanese drugmaker

Kura Oncology has signed a global partnership with the Japanese drugmaker Kyowa Kirin to develop and sell Kura’s experimental treatment for acute leukemia, the companies said Wednesday.

Kyowa is paying $330 million to Kura in exchange for licensing rights to the drug, called ziftomenib, which is in a late-stage clinical trial for a genetically defined type of advanced leukemia. Kura is also eligible to receive another $1.2 billion in potential milestone payments.

The Kura-Kyowa tie-up comes days after a competitor, Syndax Pharmaceuticals, won U.S. approval for a similar drug.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Opinion | Take Your Supplements With a Big Grain of Salt

Fred Pelzman is an associate professor of medicine at Weill Cornell, and has been a practicing internist for nearly 30 years. He is medical director

February 27, 2024

‘Striking’ Disparities in Specialty Care for Kids With Asthma on Public Insurance

Children with asthma were substantially less likely to see an outpatient specialist if they had Medicaid rather than private health insurance, a cross-sectional study revealed.

June 20, 2024

This Ex-President Also Survived an Assassination Attempt on the Campaign Trail

As they arrived in Milwaukee for this week’s Republican National Convention, reporters spotted a historical plaque on a hotel wall memorializing an assassination attempt on

July 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.